Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trial.

Autor:	de Rooij, Thijs, van Hilst, Jony, Vogel, Jantien A., van Santvoort, Hjalmar C., de Boer, Marieke T., Boerma, Djamila, van den Boezem, Peter B., Bonsing, Bert A., Bosscha, Koop, Coene, Peter-Paul, Daams, Freek, van Dam, Ronald M., Dijkgraaf, Marcel G., van Eijck, Casper H., Festen, Sebastiaan, Gerhards, Michael F., Koerkamp, Bas Groot, Hagendoorn, Jeroen, van der Harst, Erwin, de Hingh, Ignace H.
Předmět:	PANCREATECTOMY RANDOMIZED controlled trials MEDICAL research PANCREATIC surgery PANCREATICODUODENECTOMY POSTOPERATIVE pain prevention ANALGESICS COMPARATIVE studies CONVALESCENCE COST effectiveness EXPERIMENTAL design HEALTH status indicators HOSPITAL costs INGESTION LAPAROSCOPY RESEARCH methodology MEDICAL cooperation RESEARCH protocols ORAL drug administration POSTOPERATIVE pain QUALITY of life RESEARCH STATISTICAL sampling TIME EVALUATION research PAIN measurement SURGICAL robots TREATMENT effectiveness ECONOMICS
Zdroj:	Trials; 4/8/2017, Vol. 18, p1-10, 10p, 1 Color Photograph, 1 Diagram, 1 Chart
Abstrakt:	Background: Observational cohort studies have suggested that minimally invasive distal pancreatectomy (MIDP) is associated with better short-term outcomes compared with open distal pancreatectomy (ODP), such as less intraoperative blood loss, lower morbidity, shorter length of hospital stay, and reduced total costs. Confounding by indication has probably influenced these findings, given that case-matched studies failed to confirm the superiority of MIDP. This accentuates the need for multicenter randomized controlled trials, which are currently lacking. We hypothesize that time to functional recovery is shorter after MIDP compared with ODP even in an enhanced recovery setting.Methods: LEOPARD is a randomized controlled, parallel-group, patient-blinded, multicenter, superiority trial in all 17 centers of the Dutch Pancreatic Cancer Group. A total of 102 patients with symptomatic benign, premalignant or malignant disease will be randomly allocated to undergo MIDP or ODP in an enhanced recovery setting. The primary outcome is time (days) to functional recovery, defined as all of the following: independently mobile at the preoperative level, sufficient pain control with oral medication alone, ability to maintain sufficient (i.e. >50%) daily required caloric intake, no intravenous fluid administration and no signs of infection. Secondary outcomes are operative and postoperative outcomes, including clinically relevant complications, mortality, quality of life and costs.Discussion: The LEOPARD trial is designed to investigate whether MIDP reduces the time to functional recovery compared with ODP in an enhanced recovery setting.Trial Registration: Dutch Trial Register, NTR5188 . Registered on 9 April 2015. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu